Dianzani I, de Sanctis L, Smooker P M, Gough T J, Alliaudi C, Brusco A, Spada M, Blau N, Dobos M, Zhang H P, Yang N, Ponzone A, Armarego W L, Cotton R G
Dipartimento di Scienze Pediatriche e dell' Adolescenza, Università degli Studi di Torino, Italy.
Hum Mutat. 1998;12(4):267-73. doi: 10.1002/(SICI)1098-1004(1998)12:4<267::AID-HUMU8>3.0.CO;2-C.
Dihydropteridine reductase (DHPR) is an enzyme involved in recycling of tetrahydrobiopterin (BH4), the cofactor of the aromatic amino acid hydroxylases. Its deficiency is characterized by hyperphenylalaninemia due to the secondary defect of phenylalanine hydroxylase and depletion of the neurotransmitters dopamine and serotonin, whose syntheses are controlled by tryptophan and tyrosine hydroxylases. The DHPR cDNA has been cloned and mapped on 4p15.3. In the present study we report the genomic structure of the DHPR gene (QDPR). This gene includes seven exons within a range of 84-564 bp; the corresponding introns are flanked by canonic splice junctions. We also present a panel of PCR primers complementary to intronic sequences that greatly facilitates amplification of the gene and provides a genomic DNA approach for mutation detection. We have used this approach to study six patients with DHPR deficiency. Four known mutations (G23D, H158Y, IVS5G+ 1A, R221X) and two new mutations (Y150C and G218ins9bp) were found. The Y150C mutation was found in compound heterozygosity with G23D, a mutation always associated with a severe phenotype in homozygous patients. This patient has an intermediate phenotype (good response to monotherapy with BH4). The mutant enzyme for Y150C was expressed in an E. coli system. Comparison of its kinetic parameters with those of the G23D mutant enzyme showed that it is not as effective as the wild-type enzyme, but is more active than the G23D mutant. This patient's intermediate phenotype is thus due to the mild DHPR mutation Y150C. Correlations between genotypes and phenotypes were also found for the other mutations.
二氢蝶啶还原酶(DHPR)是一种参与四氢生物蝶呤(BH4)循环的酶,四氢生物蝶呤是芳香族氨基酸羟化酶的辅因子。其缺乏症的特征是由于苯丙氨酸羟化酶的继发性缺陷导致高苯丙氨酸血症,以及神经递质多巴胺和5-羟色胺的耗竭,它们的合成由色氨酸和酪氨酸羟化酶控制。DHPR cDNA已被克隆并定位在4p15.3上。在本研究中,我们报告了DHPR基因(QDPR)的基因组结构。该基因包括7个外显子,范围在84 - 564 bp之间;相应的内含子两侧是典型的剪接连接。我们还提供了一组与内含子序列互补的PCR引物,这极大地促进了该基因的扩增,并为突变检测提供了一种基因组DNA方法。我们已使用这种方法研究了6例DHPR缺乏症患者。发现了4个已知突变(G23D、H158Y、IVS5G + 1A、R221X)和2个新突变(Y150C和G218ins9bp)。Y150C突变是在与G23D的复合杂合子中发现的,G23D突变在纯合患者中总是与严重表型相关。该患者具有中间表型(对BH4单一疗法反应良好)。Y150C突变酶在大肠杆菌系统中表达。将其动力学参数与G23D突变酶的动力学参数进行比较表明,它不如野生型酶有效,但比G23D突变酶更具活性。因此,该患者的中间表型是由于轻度的DHPR突变Y150C。还发现了其他突变的基因型与表型之间的相关性。